Francis Plat

Biography

Dr. Plat joined Milestone in 2014 with responsibilities to lead the global development of Milestone’s cardiovascular programs. Dr. Plat brings over 24 years of international experience in clinical research, having worked within a number of global pharmaceutical companies. He began his industry career at Bristol Myers-Squibb in 1989 where he occupied several positions of responsibility including Medical Director in France and International Group Leader in Cardiovascular Development. He spent four years at Novartis, where he was responsible for global clinical trials as Vice President of Cardiovascular Clinical Research. Dr. Plat then joined Daiichi Sankyo in 2005 as Vice President of Cardiovascular Clinical Development. Prior to joining Milestone he was vice president and therapeutic area head, Atherosclerosis and Cardiovascular, at Merck Research Laboratories. Dr. Plat has been involved in the development and repositioning of numerous cardiovascular compounds (Vytorin, anacetrapib, vorapaxar, betrixaban, Brinavess, Effient, Azor, edoxaban, Diovan, Tareg (valsartan), Aprovel, Avalide (irbesartan), gemopatrilat, sotalol, Captopril), from ‘proof of concept’ through to registration and approval. He is a contributor to several clinical publications, conferences and book chapters in the cardiovascular area. Dr. Plat received his medical degree from the University of Paris and is a board-certified cardiologist. He spent 10 years practicing medicine in France, including post-cardiovascular surgery at the intensive care unit in the Hopital Marie Lannelongue and in cardiac rehabilitation at Broussais Hospital. Dr. Plat joined Milestone in 2014 with responsibilities to lead the global development of Milestone’s cardiovascular programs. Dr. Plat brings over 24 years of international experience in clinical research, having worked within a number of global pharmaceutical companies. He began his industry career at Bristol Myers-Squibb in 1989 where he occupied several positions of responsibility including Medical Director in France and International Group Leader in Cardiovascular Development. He spent four years at Novartis, where he was responsible for global clinical trials as Vice President of Cardiovascular Clinical Research. Dr. Plat then joined Daiichi Sankyo in 2005 as Vice President of Cardiovascular Clinical Development. Prior to joining Milestone he was vice president and therapeutic area head, Atherosclerosis and Cardiovascular, at Merck Research Laboratories. Dr. Plat has been involved in the development and repositioning of numerous cardiovascular compounds (Vytorin, anacetrapib, vorapaxar, betrixaban, Brinavess, Effient, Azor, edoxaban, Diovan, Tareg (valsartan), Aprovel, Avalide (irbesartan), gemopatrilat, sotalol, Captopril), from ‘proof of concept’ through to registration and approval. He is a contributor to several clinical publications, conferences and book chapters in the cardiovascular area. Dr. Plat received his medical degree from the University of Paris and is a board-certified cardiologist. He spent 10 years practicing medicine in France, including post-cardiovascular surgery at the intensive care unit in the Hopital Marie Lannelongue and in cardiac rehabilitation at Broussais Hospital.

Research Interest

Business Management